Evofem Biosciences to Report First Quarter 2021 Results and Provide Corporate Update on Thursday, May 6, 2021
Evofem Biosciences, Inc. (NASDAQ: EVFM) will host a webcast and conference call on May 6, 2021, at 4:30 p.m. ET to discuss its financial results and business highlights for the first quarter ended March 31, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evofem Biosciences, Inc. (NASDAQ: EVFM) will host a webcast and conference call on May 6, 2021, at 4:30 p.m. ET to discuss its financial results and business highlights for the first quarter ended March 31, 2021. Interested parties can access the live event via the company's website or by calling (866) 503-5561 in the U.S. A replay will be available for 24 hours after the event. Evofem focuses on innovative solutions for women’s health, having launched the FDA-approved product Phexxi in September 2020.
Details
News Market Reaction – EVFM
The recorded move for EVFM in the trading session of this news was -3.18%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, April 22, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the first quarter ended March 31, 2021 as follows:
Date | Thursday, May 6, 2021 |
Time | 4:30 p.m. ET (1:30 p.m. PT) |
Webcast (live and archived) | www.evofem.com under "Investors" |
Dial-in numbers | (866) 503-5561 (U.S. toll-free) or (253) 336-2965 |
Conference ID | 1899453 |
The live webcast and related slide presentation can be accessed through the Investors section of its website or directly at https://evofem.investorroom.com/2021Q1Results. Please connect to the Company's website at least 15 minutes prior to the start of the call to download any software that may be required. If participating by phone, please dial in approximately 15 minutes prior to the start of the call.
The webcast will be archived at https://evofem.investorroom.com/2021Q1Results. A telephone replay will be available for 24 hours after the call at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 1899453.
About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product, Phexxi® contraceptive vaginal gel, in the United States in September 2020. Evofem's lead product candidate, EVO100, is being evaluated for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, 'EVOGUARD.' For more information, please visit evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-report-first-quarter-2021-results-and-provide-corporate-update-on-thursday-may-6-2021-301274348.html
SOURCE Evofem Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.